Tiziana Life Sciences lead programme Foralumab is notable in that not only is this the only fully human anti-CD3 specific mAb in clinical development, with broad potential for a range of inflammatory and autoimmune diseases, but also due to the novel proprietary formulations being developed by TILS
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Tiziana Life Sciences: Transformational potential
- Published:
17 Jul 2020 -
Author:
Emma Ulker -
Pages:
23
Tiziana Life Sciences lead programme Foralumab is notable in that not only is this the only fully human anti-CD3 specific mAb in clinical development, with broad potential for a range of inflammatory and autoimmune diseases, but also due to the novel proprietary formulations being developed by TILS